 Cathie Wood-led Ark Investment Management is betting that despite recent setbacks Iovance Biotherapeutics Inc NASDAQ: IOVA will benefit from its compelling tumor-infiltrating lymphocyte TIL immunotherapy. What Happened: IOVA shares have declined 32 since Tuesday after the California-based biotech startup delayed its Biologics License Application BLA until the first half of 2022 because of FDA feedback on its potency tests. 